Amarin Corp plc (AMRN) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Amarin (AMRN): Goldman Remains Neutral as Investors Await FDA Response on ANCHOR Appeal
August 8, 2014 1:05 PM EDTGoldman Sachs maintained a Neutral rating on Amarin Corporation (NASDAQ: AMRN) with a price target of $1.90. Comments follow Q2 results. Analyst Gary Nachman said he was awaiting FDA response on its ANCHOR appeal.
"The Vascepa co-promote with Kowa began in mid-May and we have started to see a positive impact on Rxs, but it is... More
Amarin Corp plc (AMRN) Files $300M Mixed Securities Shelf
August 7, 2014 4:22 PM EDTAmarin Corp plc (NASDAQ: AMRN) filed a $300 million mixed securities shelf on form S-3.
... More